Dr Dana Rizk discusses Voyxact (sibeprenlimab-szsi), a new FDA-approved treatment to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. Dr ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results